Skip to Content
Merck
CN
All Photos(2)

Documents

Safety Information

SAB3500095

Sigma-Aldrich

Anti-JMJD2A antibody produced in rabbit

affinity isolated antibody, buffered aqueous solution

Sign Into View Organizational & Contract Pricing

Synonym(s):
Anti-Jumonji domain-containing protein 2A, Anti-KDM4A, Anti-Lysine-specific demethylase 4A
UNSPSC Code:
12352203
NACRES:
NA.41

biological source

rabbit

Quality Level

conjugate

unconjugated

antibody form

affinity isolated antibody

antibody product type

primary antibodies

clone

polyclonal

form

buffered aqueous solution

species reactivity

mouse, rat, human

technique(s)

immunohistochemistry: suitable
indirect ELISA: suitable
western blot: suitable

NCBI accession no.

UniProt accession no.

shipped in

dry ice

storage temp.

−20°C

target post-translational modification

unmodified

Gene Information

human ... KDM4A(9682)

Immunogen

JMJD2A antibody was raised against a 14 amino acid peptide from near the center of human JMJD2A.

Features and Benefits

Evaluate our antibodies with complete peace of mind. If the antibody does not perform in your application, we will issue a full credit or replacement antibody. Learn more.

Target description

Members of the Jumonji domain 2 (JMJD2) family contain a JmjN domain, a JmjC domain, a JD2H domain, two TUDOR domains, and two PHD-type zinc fingers. The first member of this group, JMJD2A, is widely expressed in human tissues and cell lines and functions as a trimethylation-specific demethylase, converting specific trimethylated histone residues to the dimethylated form, and as a transcriptional repressor. JMJD2A can also form a complex with the androgen receptor (AR), a transcription factor that is pivotal for the development of prostate cancer. Overexpression of JMJD2A stimulates AR function and this stimulation is dependent on JMJD2A catalytic activity, suggesting that JMJD2A might be a critical protein with roles in cell proliferation and oncogenesis.

Linkage

The action of this antibody can be blocked using blocking peptide SBP3500095.

Physical form

Supplied at approx. 1 mg/mL in phosphate buffered saline containing 0.02% sodium azide.

related product

Product No.
Description
Pricing

WGK

WGK 2

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable

Regulatory Information

新产品

Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Qi Hu et al.
International journal of molecular medicine, 37(1), 189-196 (2015-11-05)
The epigenetic modification of vascular smooth muscle cell (VSMC) phenotypic switching, proliferation, migration, apoptosis and extracellular matrix synthesis is known to occur in atherosclerosis. The aim of the present study was to investigate the effects of IOX1, a Jumonji domain-containing

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service